Sentence examples for in peripheral doses from inspiring English sources

Strategies for a reduction in peripheral doses in radiotherapy, e.g. by defining indications for ion therapy.

The increasing interest of the medical community to radioinduced second malignancies due to photoneutrons in patients undergoing high-energy radiotherapy, has stimulated in recent years the study of peripheral doses, including the development of some dedicated active detectors.

The issue of how a small amount of anti-Aβ monoclonal antibody (mAb) present in the brain following peripheral dosing can have a therapeutic effect on plaque pathology has posed a dilemma for the field.

Dose prescription and treatment evaluation were based on recommendations in the International Commission on Radiation Units and Measurements (ICRU), Report 58 and included the parameters mean central dose (MCD), average peripheral dose, dose homogeneity index (DHI), and the dimensions of the low- and high-dose regions.

The results showed that LLDT-8 up-regulated OPG expression on CD3+ T leukomonocyte in peripheral blood at doses of 25 nM and 50 nM, and increased the ratio of OPG/RANKL at the dose of 50 nM.

In the first phase of the trial, AG014699 was dose-escalated to establish the PARP inhibitory dose (PID) in peripheral blood lymphocytes (PBLs) with no dose-limiting toxicity observed.

Thus, this marker can be a tool in predicting the prognosis of patients with TBI and used as a marker of lipid peroxidation which can be dosed in peripheral blood sample.

The ex vivo assay demonstrated a significant inhibition of GM-CSF-induced SOCS3 expression 4 h after dosing in peripheral white blood cells from subjects in the 1.0 and 3.0 mg/kg cohorts, but not the 0.3 mg/kg cohort, consistent with full receptor occupancy as predicted from non-compartmental analysis.

Tb4SO induced the phosphorylation of ERK1/2 in peripheral blood-derived monocytes in dose-dependent manner.

The PARP inhibitory dose (PID), defined as >50% decrease in PARP activity 24 h after dosing as evaluated in peripheral blood mononuclear cells (PBMCs), was determined to be 12 mg/m.

There was a dose-related increase in peripheral edema (Table 1).